دورية أكاديمية
9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial
| العنوان: | 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial |
|---|---|
| المؤلفون: | Gerhard-Hartmann, Elena, Goergen, Helen, Bröckelmann, Paul J., Mottok, Anja, Steinmüller, Tabea, Grund, Johanna, Zamò, Alberto, Ben-Neriah, Susana, Sasse, Stephanie, Borchmann, Sven, Fuchs, Michael, Borchmann, Peter, Reinke, Sarah, Engert, Andreas, Veldman, Johanna, Diepstra, Arjan, Klapper, Wolfram, Rosenwald, Andreas |
| سنة النشر: | 2022 |
| المجموعة: | Würzburg University: Online Publication Service |
| مصطلحات موضوعية: | ddc:610 |
| الوصف: | High programmed cell death 1 ligand 1 (PD-L1) protein expression and copy number alterations (CNAs) of the corresponding genomic locus 9p24.1 in Hodgkin- and Reed–Sternberg cells (HRSC) have been shown to be associated with favourable response to anti-PD-1 checkpoint inhibition in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In the present study, we investigated baseline 9p24.1 status as well as PD-L1 and major histocompatibility complex (MHC) class I and II protein expression in 82 biopsies from patients with early stage unfavourable cHL treated with anti-PD-1-based first-line treatment in the German Hodgkin Study Group (GHSG) NIVAHL trial (ClinicalTrials.gov Identifier: NCT03004833). All evaluated specimens showed 9p24.1 CNA in HRSC to some extent, but with high intratumoral heterogeneity and an overall smaller range of alterations than reported in advanced-stage or r/r cHL. All but two cases (97%) showed PD-L1 expression by the tumour cells in variable amounts. While MHC-I was rarely expressed in >50% of HRSC, MHC-II expression in >50% of HRSC was found more frequently. No obvious impact of 9p24.1 CNA or PD-L1 and MHC-I/II expression on early response to the highly effective anti-PD-1-based NIVAHL first-line treatment was observed. Further studies evaluating an expanded panel of potential biomarkers are needed to optimally stratify anti-PD-1 first-line cHL treatment. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/25835Test; urn:nbn:de:bvb:20-opus-258358; https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-258358Test; https://doi.org/10.1111/bjh.17793Test; https://opus.bibliothek.uni-wuerzburg.de/files/25835/Gerhard_Hartmann_Haematol.pdfTest |
| DOI: | 10.1111/bjh.17793 |
| الإتاحة: | https://doi.org/10.1111/bjh.17793Test https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/25835Test https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-258358Test https://opus.bibliothek.uni-wuerzburg.de/files/25835/Gerhard_Hartmann_Haematol.pdfTest |
| حقوق: | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.deTest ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.2B97B466 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/bjh.17793 |
|---|